LY3437943, a novel triple GIP, GLP-1, and glucagon receptor agonist in people with type 2 diabetes: a phase 1b, multicentre, double-blind, placebo-controlled, randomised, multiple-ascending dose trial
Urva S, Coskun T, Loh MT, et al. The Lancet 2022;400:1869-1881.
What it found
The half-life was about 6 days. Gastrointestinal events were the most common side effects. At the three highest doses, HbA1c fell by 1.2% to 1.6% more than placebo, and weight fell by up to 8.96 kg more than placebo in the highest-dose group.
Limitations
Very small groups (9 to 12 people per dose), 12 weeks, and 29 of 72 participants left the study early.
Research and education only. Not medical advice. Many peptides on this site are not approved by the FDA for human use. Doses shown are the ones used in published studies and are not a recommendation. Talk to a licensed clinician before using any of them. Read the full disclaimer.